At the time of writing, Regeneron Pharmaceuticals, Inc [REGN] stock is trading at $788.00, up 1.29%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The REGN shares have gain 3.37% over the last week, with a monthly amount drifted -4.42%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Regeneron Pharmaceuticals, Inc [NASDAQ: REGN] stock has seen the most recent analyst activity on November 15, 2024, when Wolfe Research initiated its Outperform rating and assigned the stock a price target of $1150. Previously, Citigroup started tracking the stock with Neutral rating on November 14, 2024, and set its price target to $895. On September 24, 2024, downgrade downgraded it’s rating to Market Perform and revised its price target to $1077 on the stock. Bernstein started tracking the stock assigning a Outperform rating and suggested a price target of $1125 on March 12, 2024. RBC Capital Mkts upgraded its rating to a Outperform and raised its price target to $1076 on January 12, 2024. Deutsche Bank started tracking with a Hold rating for this stock on November 09, 2023, and assigned it a price target of $800. In a note dated November 03, 2023, Raymond James upgraded an Outperform rating on this stock but restated the target price of $950.
For the past year, the stock price of Regeneron Pharmaceuticals, Inc fluctuated between $735.95 and $1211.20. Currently, Wall Street analysts expect the stock to reach $1135.2 within the next 12 months. Regeneron Pharmaceuticals, Inc [NASDAQ: REGN] shares were valued at $788.00 at the most recent close of the market. An investor can expect a potential return of 44.06% based on the average REGN price forecast.
Analyzing the REGN fundamentals
According to Regeneron Pharmaceuticals, Inc [NASDAQ:REGN], the company’s sales were 13.85B for trailing twelve months, which represents an 10.65% jump. Gross Profit Margin for this corporation currently stands at 0.84% with Operating Profit Margin at 0.29%, Pretax Profit Margin comes in at 0.36%, and Net Profit Margin reading is 0.34%. To continue investigating profitability, this company’s Return on Assets is posted at 0.12, Equity is 0.17 and Total Capital is 0.12. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 773.67 points at the first support level, and at 759.34 for the second support level. However, for the 1st resistance point, the stock is sitting at 801.66, and for the 2nd resistance point, it is at 815.32.
Ratios To Look Out For
It is important to note that Regeneron Pharmaceuticals, Inc [NASDAQ:REGN] has a current ratio of 5.28. In addition, the Quick Ratio stands at 4.46 and the Cash Ratio stands at 0.55. Considering the valuation of this stock, the price to sales ratio is 6.34, the price to book ratio is 2.96 and price to earnings (TTM) ratio is 19.50.
Transactions by insiders
Recent insider trading involved McCourt Marion, EVP Commercial, that happened on Nov 01 ’24 when 1000.0 shares were sold. Officer, MARION E MCCOURT completed a deal on Nov 01 ’24 to buy 1000.0 shares. Meanwhile, Director RYAN ARTHUR F sold 100.0 shares on Oct 01 ’24.
